News

LAU-7b featured in The Pharmaceutical Journal among next-generation antivirals targeting COVID-19

19 January 2023

LAU-7b featured in The Pharmaceutical Journal (The Royal Pharmaceutical Society) among next-generation antivirals targeting COVID-19

Read More

Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

3 November 2022

LAU-7b first inflammation-controlling drug to demonstrate clinical benefit in adults with CF, complementary to administration of CFTR modulators.Study achieves clinically meaningful...

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022